Neuroendocrine cancer pancreas prognosis.

Archive of Clinical Cases, Vol 2, No 1 (2015)

One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase. They change related to the disease progression, regardless therapy.

Создания, которых вы с папой называете "гигантскими светляками", проводят над каждым полем точно рассчитанное время - каждую неделю или месяц. И с водой у них обходятся так же бережливо, как и с фотонами.

- А где Эпонина. - поинтересовалась Николь, глядя на уставленный едой стол посреди комнаты.

Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods. All the patients had at least one assay per year.

Revista Romana de Medicina de Laborator

The dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered. One case of known diabetes needed insulin but interferon therapy was also added during this time period.

  • Cancer peritoneal expectativa de vida
  • Поинтересовалась .

  • Parazit u psa
  • Papillary thyroid cancer signs and symptoms
  • Giant cell papilloma

The chromogranin A neuroendocrine cancer pancreas prognosis sustained high values for all the 9 cases, marking the disease progression. The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms.

The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are neuroendocrine cancer pancreas prognosis correlated.

neuroendocrine cancer pancreas prognosis cancer penian cauze

Rezumat Tumorile neuroendocrine NET sunt mult mai frecvente în ultimele decade. Unul din intrumentele majore de evaluare în această patologie este reprezentat de dozarea markerilor neuroendocrini precum cromogranina A, serotonina, acidul 5-hidroxi indolacetic urinar şi enolaza neuronal specifică.

Cancer - Pancreatic NET (Neuroendocrine Tumours) Treatments - intellicig.ro

Aceştia se schimbă cu progresia tumorală, indiferent de terapie. O parte din medicamentele folosite în NET precum analogii de somatostatin de exemplu, octreotid interferă cu metabolismul glucozei. Am analizat într-un studiu retrospectiv de-a lungul a 2 ani dinamica markerilor NET şi profilul glicemic. Material si metode. Toţi pacienţii au avut cel puţin o evaluare pe an.

Most Downloaded Articles

Doza de octreotid a variat de la 20 la 50 mg lunar. Glicemia s-a modificat nesemnificativ de la bază după 2 ani. Nu s-a înregistrat nici un caz nou de diabet. O pacientă a necesitat insulină pentru diabetul preexistent dar între timp s-a adaugat şi terapie cu interferon Cromogranina A a avut valori mari sustinute pentru toate cele 9 cazuri, sugerând progresia bolii.

Enolaza neuronal specifică a crescut semnificativ iar serotonina serică şi 5HIIA au crescut considerabil în 2 cazuri cu simptome neuroendocrine cancer pancreas prognosis de sindrom carcinoid.

Markerii NET şi metabolismul glucidic sunt instrumente foarte utile in managementul tumorilor neuroendocrine, totusi acestea nu se coreleaza.

Cuvinte cheie: cromogranina A ; tumora neuroendocrina ; serotonina References 1. Neuroendocrine tumors.

detoxifiere prin osmoza human papillomavirus noknel

Endocr Relat Cancer. DOI: Oberndorfer S. Karzinoide tumoren des dunndarms. Frank Z Pathol. Google Scholar 3.

simptome cancer la plamani tratament

Carcinoid Tumors. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry.

Adv Anat Pathol. Chromogranins A, B, C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci.

papilloma a cellule squamose cute

Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Regul Pept.

The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol.

Доктор Тернер подтвердил мнение Макса - рана действительно была не слишком серьезной - и предписал ему короткий отдых для выздоровления. - А чего, буду выполнять, - ответил Макс, подмигнув Эпонине.

Google Scholar The dedifferentiation of neuroendocrine tumor metastases: myth or reality? PubMed Google Scholar Octreotide for the treatment of hypoglycemia after insulin glargine overdose.

neuroendocrine cancer pancreas prognosis anemie genetica

J Emerg Med. Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding?

Treatment of neuroendocrine cancer pancreas prognosis midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.

Acta Oncol.

Artikelempfehlungen Abstract Neuroendocrine cancer pancreas prognosis neuroendocrine tumors NETs are more frequent during the last decades. One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase. They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile.

Long-term vaccino papillomavirus gardasil outcome of somatostatin analogues for treatment of pregressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.